GENE ONLINE|News &
Astellas Resumes XLMTM Gene Therapy Trials Five Years After Initial Study
Astellas is resuming gene therapy trials for X-linked myotubular myopathy (XLMTM) after a previous trial yielded mixed results, including both significant recoveries and fatalities among participants. The company aims to improve outcomes using a revised approach to treatment.
The decision to restart the trials comes five years after initial studies revealed the potential of gene therapy to treat this rare disease, which primarily affects young boys. While some patients experienced remarkable recoveries, others tragically died during the first round of trials. Astellas is now revisiting the gene therapy with modifications, hoping to build on the successes and address the challenges encountered in the earlier research.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: May 11, 2026
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
LATEST
Hilton Partners With Big Brothers Big Sisters to Provide Hospitality Career Training for Youth
2026-06-18
Pacific Life Launches Income Horizon Collective Investment Trust Series for Retirement Plans
2026-06-18
Synovis Micro Companies Alliance to Distribute MediThinQ SHIYA 3D Visualization Platform Globally
2026-06-18
Diamond Estates Wines & Spirits Inc. Renews Investor Relations Agreement with Atrium Research
2026-06-18
EVENT
2026-08-07
Healthy Ageing Tech Show (7-9 Aug, TAIPEI WTC) (Longevity, elder care & ageing tech)
Taipei, Taiwan
